ReviewFrontiers in medicine2021
Emerging Radionuclides in a Regulatory Framework for Medicinal Products - How Do They Fit?
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Review
- To be GMP or not to be- a radionuclide's question.EJNMMI radiopharmacy and chemistry · 2025Article
- Force Fields, Quantum-Mechanical- and Molecular-Dynamics-Based Descriptors of Radiometal-Chelator Complexes.Molecules (Basel, Switzerland) · 2024Article
- Radiopharmaceutical small-scale preparation in Europe: will we be able to harmonize the situation?EJNMMI radiopharmacy and chemistry · 2024Review
- How to design a theranostic trial?Endocrine oncology (Bristol, England) · 2024Review
- Role of Pure Technetium Chemistry: Are There Still Links to Applications in Imaging?Inorganic chemistry · 2023Article
- Radiometal chelators for infection diagnostics.Frontiers in nuclear medicine · 2023Article
- Production of GMP-Compliant Clinical Amounts of Copper-61 Radiopharmaceuticals from Liquid Targets.Pharmaceuticals (Basel, Switzerland) · 2022Article
- EANM position on the in-house preparation of radiopharmaceuticals.European journal of nuclear medicine and molecular imaging · 2022Article
- Cyclotrons Operated for Nuclear Medicine and Radiopharmacy in the German Speaking D-A-CH Countries: An Update on Current Status and Trends.Frontiers in nuclear medicine · 2022Article
- Cold Kit Labeling: The Future ofFrontiers in medicine · 2022Review
- Radiolabeled PSMA Inhibitors.Cancers · 2021Review
- Obstacles and Recommendations for Clinical Translation of Nanoparticle System-Based Targeted Alpha-Particle Therapy.Materials (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent years have seen the establishment of several radionuclides as medicinal products in particular in the setting of theranostics and PET. [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.